Filing Details

Accession Number:
0001415889-25-001301
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-10 17:31:52
Reporting Period:
2025-01-07
Accepted Time:
2025-01-10 17:31:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967163 Anish Patel C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-01-07 10,700 $1.12 10,700 No 4 M Direct
Common Stock Acquisiton 2025-01-07 2,000 $2.48 12,700 No 4 M Direct
Common Stock Acquisiton 2025-01-07 9,000 $2.48 21,700 No 4 M Direct
Common Stock Disposition 2025-01-07 20,260 $24.15 1,440 No 4 S Direct
Common Stock Disposition 2025-01-07 1,440 $24.56 0 No 4 S Direct
Common Stock Disposition 2025-01-07 6,577 $24.17 336,734 No 4 S Indirect See footnote
Common Stock Disposition 2025-01-07 90 $24.60 336,644 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2025-01-07 10,700 $0.00 10,700 $1.12
Common Stock Employee Stock Option (right to buy) Disposition 2025-01-07 2,000 $0.00 2,000 $2.48
Common Stock Employee Stock Option (right to buy) Disposition 2025-01-07 9,000 $0.00 9,000 $2.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
67 2030-06-16 No 4 M Direct
827 2031-03-25 No 4 M Direct
44,342 2031-03-25 No 4 M Direct
Footnotes
  1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
  2. This transaction was executed in multiple trades at prices ranging from $23.5364 to $24.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $24.54 to $24.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. This transaction was executed in multiple trades at prices ranging from $23.595 to $24.585. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. The shares are held by The Patel / Dong Family Trust.
  6. This transaction was executed in multiple trades at prices ranging from $24.60 to $24.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
  8. The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on January 14, 2021.